Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Vergote I, et al. Among authors: berek js. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
Specific keynote: immunological therapy for ovarian cancer.
Berek JS, Dorigo O, Schultes B, Nicodemus C. Berek JS, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S105-9; discussion S110-3. doi: 10.1006/gyno.2002.6695. Gynecol Oncol. 2003. PMID: 12586097 Review. No abstract available.
Progress in the management of gynecologic cancer: consensus summary statement.
Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Cannistra SA, et al. Among authors: berek js. J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. doi: 10.1200/JCO.2003.04.003. J Clin Oncol. 2003. PMID: 12743127 No abstract available.
Intraperitoneal chemotherapy for ovarian cancer.
Hamilton CA, Berek JS. Hamilton CA, et al. Among authors: berek js. Curr Opin Oncol. 2006 Sep;18(5):507-15. doi: 10.1097/01.cco.0000239892.21161.18. Curr Opin Oncol. 2006. PMID: 16894301 Review.
CA125: megadaltons of novel opportunities.
Dorigo O, Berek JS. Dorigo O, et al. Among authors: berek js. Gynecol Oncol. 2007 Mar;104(3):505-7. doi: 10.1016/j.ygyno.2007.01.035. Gynecol Oncol. 2007. PMID: 17306691 No abstract available.
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P. Tian WJ, et al. Among authors: berek js. Ann Surg Oncol. 2012 Feb;19(2):597-604. doi: 10.1245/s10434-011-1873-2. Epub 2011 Jul 6. Ann Surg Oncol. 2012. PMID: 21732142
311 results